Portola Pharmaceuticals

Portola Pharmaceuticals

World Rank (Aug-2026)
5432
World Rank (Jan-05-2024)
5,432
World Rank (Jul-30-2023)
5,432
World Rank (Jan-07-2022)
5,432
World Rank (Jan-01-2021)
5,432
Headquarters Country
USA
Top Healthcare Companies in USA
Top Pharmaceutical Companies in USA
Headquarters City/State
California
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
117 Million USD
Annual Operating Income in USD
-271 Million USD
Annual Net Income in USD
-291 Million USD
Annual Results for Period Ending
For year ending December-2019
Total Assets in USD
578 Million USD
Total Liabilities in USD
449 Million USD
Total Equity in USD
130 Million USD
Balance Sheet for Period Ending
As of December-2019
Business Sector
Healthcare
Pharmaceutical
HealthCare Products
Biotechnology
Company Profile

Portola Pharmaceuticals is a Biotechnology company. It is having more than 380 employees and has offices around the globe and serves patients in more than 50 countries. The company has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome (aHUS) as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder. The headquarters is in USA.

Alexion acquired Portola Pharmaceuticals for 1.41 billion USD.

Share